Immix Biopharma, Inc.
NASDAQ:IMMXBiotechnology
+$0.09 today
- Market cap
- $590.04M
- Beta
- 0.10
- P/E (TTM)
- -10.1
- EPS (TTM)
- -$0.91
Volume 1.13M
Average 1.07M
Returns on capital
Immix Biopharma, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-31.4%
avg -62.2%
ROIC
-28.7%
avg -66.9%
ROA
-28.1%
avg -100.7%
Analysis
ROA is currently the strongest return metric at -28.1% versus its period average of -100.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Ilya Rachman | Co-Founder, CEO, Chief Scientific Officer & Chairman | USD 760K | 53 | — | — |
Gabriel Morris | President, CFO & Director | USD 760K | 39 | — | — |
Graham Ross FFPM | Chief Medical Officer & Head of Clinical Development | USD 88.59K | 66 | — | — |
David Marks | Chief Medical Officer of Cell Therapy | — | — | — | — |
Vladimir Torchilin | Scientific Co-Founder | — | 79 | — | — |
Mel Davis-Pickett | Head of CMC Technical Development | — | — | — | — |
Michael A. Grabow | Chief Commercial Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$10,042.42
Sells
0
$0.00
Net Transaction Value
+$10,042.42
Net buying
Most Active
Rachman Ilya M
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Dec 10, 25Dec 10, 2025 | Rachman Ilya M Direct | Buy | $5K$4,975.82 |
| Dec 10, 25Dec 10, 2025 | Morris Gabriel S Direct | Buy | $5.1K$5,066.60 |
Summary
Insiders reported 2 buys worth $10,042.42 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $10,042.42. Rachman Ilya M was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Immix Biopharma, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about IMMX's management, answered from reported figures.
Who manages IMMX?
Immix Biopharma, Inc. (IMMX) lists 7 active executives. The top listed executive is David Marks, Chief Medical Officer of Cell Therapy.
Are IMMX insiders buying or selling?
Recent insider activity shows net buying of $21.80M.
Continue the stock analysis
Jump to another research area for this company.